Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, randomized, phase3 trial to evaluate the efficacy of
Camrelizumab in patients with relapsed or refractory classic Hodgkin's lymphoma. Participants
will be randomized to receive either Camrelizumab monotherapy or chemotherapy of
investigators' choice.
The primary hypotheses of this study are that treatment with Camrelizumab prolongs
Progression-free Survival (PFS) in participants with relapsed or refractory Classical Hodgkin
Lymphoma compared to treatment with Chemotherapy.